Minimal residual disease in hypopigmented mycosis fungoides

J Am Acad Dermatol. 2006 May;54(5 Suppl):S198-201. doi: 10.1016/j.jaad.2005.08.044.

Abstract

We describe the case of a 13-year-old boy with stage I hypopigmented mycosis fungoides in whom minimal residual disease was detected with T-cell receptor gamma-polymerase chain reaction after the disease was in complete clinical remission. We further cloned and sequenced the T-cell receptor gamma-polymerase chain reaction product of the lesion in remission and found that the original T-cell clone still existed in decreased amounts. The patient was followed up for 3 1/2 years without any new lesions developing. The clinical significance of this residual malignant T-cell clone in mycosis fungoides remains to be elucidated.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Agents, Alkylating / therapeutic use
  • Carmustine / therapeutic use
  • Humans
  • Male
  • Mycosis Fungoides / complications
  • Mycosis Fungoides / drug therapy
  • Mycosis Fungoides / pathology*
  • Neoplasm, Residual / etiology*
  • Neoplasm, Residual / metabolism
  • Neoplasm, Residual / pathology*
  • Pigmentation Disorders / complications
  • Pigmentation Disorders / pathology*
  • Polymerase Chain Reaction
  • Receptors, Antigen, T-Cell, gamma-delta / metabolism
  • Remission Induction
  • Skin Neoplasms / complications
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / pathology*
  • Skin Pigmentation

Substances

  • Antineoplastic Agents, Alkylating
  • Receptors, Antigen, T-Cell, gamma-delta
  • Carmustine